Outcome
. | ATG dose . | . | . | |
|---|---|---|---|---|
. | High n = 46 (%) . | Low n = 55 (%) . | P . | |
| Progression or relapse | 24 (52) | 16 (29) | .02 | |
| Patients surviving in | ||||
| Complete remission | 10 (22) | 14 (25) | ||
| Partial remission | 2 (4) | 9 (16) | ||
| Stable disease | 0 | 10 (18) | .06 | |
| Progressive disease | 2 (4) | 2 (4) | ||
| Deaths | 32 (70) | 20 (36) | ||
| Causes of death | ||||
| Disease recurrence or progression | 21 (46) | 13 (65) | ||
| Transplantation-related mortality | ||||
| Acute GVHD | 5 (16)* | 3 (15)* | ||
| Chronic GVHD | 0 | 4 (20) | ||
| Infections | 5 (16) | 0 | NS | |
| Multiorgan failure | 1 (3) | 0 | ||
. | ATG dose . | . | . | |
|---|---|---|---|---|
. | High n = 46 (%) . | Low n = 55 (%) . | P . | |
| Progression or relapse | 24 (52) | 16 (29) | .02 | |
| Patients surviving in | ||||
| Complete remission | 10 (22) | 14 (25) | ||
| Partial remission | 2 (4) | 9 (16) | ||
| Stable disease | 0 | 10 (18) | .06 | |
| Progressive disease | 2 (4) | 2 (4) | ||
| Deaths | 32 (70) | 20 (36) | ||
| Causes of death | ||||
| Disease recurrence or progression | 21 (46) | 13 (65) | ||
| Transplantation-related mortality | ||||
| Acute GVHD | 5 (16)* | 3 (15)* | ||
| Chronic GVHD | 0 | 4 (20) | ||
| Infections | 5 (16) | 0 | NS | |
| Multiorgan failure | 1 (3) | 0 | ||
Because of rounding, not all percentages total 100.
NS indicates not significant.
One donor leukocyte infusion induced GVHD.